文献速递创伤与烧伤重症综合管理与镇静镇痛

重型儿童创伤性脑损伤的分子架构:整合组学揭示治疗通路

The molecular architecture of severe pediatric traumatic brain injury: integrated omics reveal therapeutic pathways.
PubMed 文献 · Crit Care · 2025-12-09
一句话结论前瞻性队列整合转录组与代谢组显示,重型儿童TBI后9天内存在趋同的宿主反应,涉及炎症免疫激活、代谢紊乱、肠脑轴扰动及第9天不完全恢复的IGH、IGK、IGL克隆扩增,提示潜在可靶向通路。

该前瞻性观察性队列纳入17例重型儿童TBI患者(中位年龄13.1岁,中位GCS 3分,中位ISS 29分)及性别年龄匹配对照,于2022年5月至2023年11月入组,在PICU 9天护理期间三个时间点行全血转录组和血清代谢组分析。结果显示各时间点转录组和代谢特征存在重叠:急性期即出现炎症免疫激活、代谢失调和肠脑轴扰动;TRAV35和ANXA2R等早期T细胞浸润标志物与GCS高度相关,溶血磷脂酰胆碱18:0与NK细胞活化高度相关;多种肠道代谢物(如吲哚-3-丙酸IPA)和肠道菌群RNA特征在TBI后早期血液中升高;时间点1的腐胺升高与第9天红细胞刺激高度相关;第9天多种脂质与住院时长和GOS-E Peds相关,且代谢组和转录组均显示不完全恢复,以高度特异性的TBI相关IGH、IGK、IGL克隆扩增为标志。作者认为这些趋同的宿主反应揭示了潜在可靶向的生物学通路,为开发重型儿童TBI新治疗策略打开大门。

要点

  • 17例重型儿童TBI患者(中位GCS 3分、ISS 29分)在PICU 9天内三个时间点行全血转录组和血清代谢组分析,各时间点转录组和代谢特征存在重叠。
  • 急性期即出现炎症和免疫激活、代谢失调及肠脑轴扰动;TRAV35和ANXA2R等早期T细胞浸润标志物与GCS高度相关,溶血磷脂酰胆碱18:0与NK细胞活化高度相关。
  • 多种肠道代谢物如吲哚-3-丙酸(IPA)及肠道菌群RNA特征在TBI后早期血液中升高;时间点1腐胺升高与第9天红细胞刺激高度相关。
  • 第9天多种脂质与住院时长和GOS-E Peds相关;第9天代谢组和转录组均显示不完全恢复,以高度特异性TBI相关IGH、IGK、IGL克隆扩增为标志。
  • 作者认为趋同的宿主反应揭示潜在可靶向生物学通路,为重型儿童TBI新治疗策略开发打开大门。

适用人群与场景

  • 前瞻性观察性队列纳入17例重型儿童TBI患者,中位年龄13.1岁,中位GCS 3分,中位ISS 29分,无既存神经系统合并症或非意外创伤,于2022年5月至2023年11月入组,并纳入性别和年龄匹配对照。
  • 研究场景为PICU 9天护理期间,于三个不同时间点采血行全血转录组和血清代谢组分析。

研究设计与关键结果

  • 研究类型为前瞻性观察性队列,样本量17例重型儿童TBI患者及性别年龄匹配对照,于2022年5月至2023年11月入组,在PICU 9天护理期间三个时间点行全血转录组和血清代谢组分析。
  • 尽管损伤机制和临床表现异质,各时间点转录组和代谢特征存在重叠;急性期即出现炎症和免疫激活、代谢失调及肠脑轴扰动。
  • TRAV35和ANXA2R等早期T细胞浸润标志物与GCS高度相关,溶血磷脂酰胆碱18:0与NK细胞活化高度相关。
  • 多种肠道代谢物如吲哚-3-丙酸(IPA)及肠道菌群RNA特征在TBI后早期血液中升高;时间点1腐胺升高与第9天红细胞刺激高度相关。
  • 第9天代谢组中多种脂质与住院时长和GOS-E Peds相关;第9天代谢组和转录组均显示不完全恢复,以高度特异性TBI相关IGH、IGK、IGL克隆扩增为标志。

证据类型、等级与局限

  • 证据类型:前瞻性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管损伤机制和临床表现异质,趋同的宿主反应揭示潜在可靶向的生物学通路,为重型儿童TBI新治疗策略的开发打开大门。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Traumatic brain injury (TBI) remains a leading cause of death and long-term disability in children worldwide. Despite its impact, current clinical management is limited to supportive care, with no FDA-approved therapies to reduce mortality or mitigate lasting neurological consequences. This study presents, to our knowledge, the first integrated multi-omics analysis combining transcriptomic and metabolomic data from pediatric patients with severe TBI spanning both acute and subacute phases offering novel insights into the molecular pathways underlying injury and recovery.

METHODS: In this prospective, observational cohort study seventeen severe pediatric TBI patients (median age of 13.1 years, median Glasgow Coma Scale (GCS) of 3, and median Injury Severity Score (ISS) of 29) with no pre-existing neurological comorbidities or non-accidental trauma, and corresponding sex and age-matched controls were enrolled between May 2022 and November 2023. The longitudinal bulk transcriptomic analysis of whole blood and metabolomic profiling of serum were performed at three distinct timepoints. The resulting multi-omics datasets were subsequently integrated with validated clinical severity scoring systems to assess changes over a nine-day period of care in the pediatric intensive care unit (PICU).

RESULTS: We showed that despite the heterogeneity of mechanism and presentation, there was overlap in the transcriptomic and metabolic signatures at each timepoint. There were immediate signs of inflammatory and immune activation, metabolic dysregulation, disturbance of the gut-brain axis in the acute phase. Early markers of T-cell infiltration, such as TRAV35 and ANXA2R, are highly correlated with GCS, and lysophosphatidylcholine 18:0 is highly correlated with NK-cell activation. Multiple gut metabolites, such as indole-3-propionic acid (IPA), and RNA signatures of gut flora are elevated in blood early after TBI. Putrescine elevation at time point one highly correlates with Day 9 red blood cell stimulation. At Day9, multiple lipid species in the metabolome are associated with length of stay and Glasgow Outcome Scale-Extended (GOS-E Peds). By Day 9, both the metabolome and transcriptome show incomplete recovery, marked by highly specific TBI IGH, IGK, and IGL clonal expansion.

CONCLUSIONS: Despite the heterogeneity in injury mechanisms and clinical presentations, our findings reveal a convergent host response, characterized by shared transcriptomic and metabolic signatures across all time points. This convergence highlights potentially targetable biological pathways and opens the door to the development of novel therapeutic strategies for severe pediatric TBI.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Hussain E, Prokop JW, Nonnemacher E, et al. The molecular architecture of severe pediatric traumatic brain injury: integrated omics reveal therapeutic pathways. Crit Care. 2025. PMID: 41361486. doi:10.1186/s13054-025-05789-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。